# A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

> **NCT06545617** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Bio-Thera Solutions**

## Conditions studied

- Platinum-resistant Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** BAT8006 for Injection

## Key facts

- **NCT ID:** NCT06545617
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-31
- **Primary completion:** 2026-03-10
- **Final completion:** 2028-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Reconsideration of the subsequent international development of BAT8006
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545617, "A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06545617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*